LMLisa Maier

Lisa Maier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lisa Maier has a total of 359 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Overconsumption of low-digestible sugars can increase susceptibility to Salmonella Typhimurium infection

    by Bidong D. Nguyen, Sandra Y. Wotzka, Lisa Maier, Céline Fetz, Yves Steiger, Sanne Kroon, Elena F. Verdu, Nermin Akduman, Markus Arnoldini, Dorothée L. Berthold, et al.

    Low-digestible carbohydrates (LDCs), including dietary fibers and sugars that resist absorption, are generally considered beneficial for the gut microbiota. However, we show that acute overconsumption of certain LDCs, particularly low-digestible sugars (LDSs), such as arabinose, lactulose, and polyols commonly used as sugar substitutes, can compromise colonization resistance against the common foodborne pathogen Salmonella enterica serovar Typhimurium. LDS overconsumption results in elevated fecal pathogen loads, systemic dissemination, and colitis in infected mice. Mechanistic analysis of arabinose overconsumption revealed that rapid fermentation acidifies the intestinal environment, perturbs the microbiota, alters gut-luminal short-chain fatty acid levels and elevated amino acid availability, which can support pathogen growth. Additionally, this perturbation impacts virulence by broadening tissue tropism (e.g. expansion to small intestine) and selecting for invasive Salmonella . Unlike antibiotic perturbations, Salmonella colonization requires SPI-1 and SPI-2 Type-III-secretion systems, linking virulence to pathogen fitness. These findings reveal how dietary perturbations can impact the gut ecosystem in ways that not only compromise colonization resistance but also enhance pathogen virulence.

  • Open Access

    A host-directed virulence factor of Clostridium perfringens is modulated by gut commensal strains

    by Julia Schumacher, Paolo Stincone, Johanna Rapp, Timo N. Lucas, Carlos Llaca-Bautista, Francesca Barletta, Mirita Franz, Boris Maček, Daniel H. Huson, Lisa Maier, et al.

  • The human gut microbiome primes fever after vaccination

    by Kelsey E. Huus, Hirohito Abo, Yi Han Tan, Ezgi Atay, Héloïse Rytter, Ronald Keller, Silke Dauser, Dai Long Vu, Meghan B. Azad, Rob Knight, et al.

    Fever is a common adverse reaction to vaccination, contributing to vaccine hesitancy and reduced uptake. To understand variation in fever risk, we longitudinally profiled fecal microbiota, oral temperature, and serological markers in 171 healthy adults receiving Severe acute respiratory syndrome coronavirus 2 mRNA vaccines. Fever risk correlated with low-grade intestinal inflammation, increased abundance of flagellated Lachnospiraceae bacteria, and increased flagellin expression prevaccine. Microbiomes from fever-high donors triggered stronger inflammation in human intestinal organoids and drove flagellin-dependent vaccine reactions in gnotobiotic mice. Moreover, microbiome flagellin phenotypes and murine vaccine reactions were modifiable by diet. Consistent with this, human fever risk was associated with self-reported diet and metabolic markers. These findings identify the gut microbiome as a driver of vaccine-induced fever, suggesting that microbiome-targeting strategies could modulate immune tone and improve vaccine side effects.


  • Open Access

    Lithocholic acid modulates the growth of butyrate-producing bacteria and is decreased in the feces of stunted children

    by Kelsey E. Huus, Julian R. Garneau, Nermin Akduman, Simon Yersin, Jun Han, Mariia A. Beliaeva, Cordula Gekeler, Leonardo Boldt, Munir Winkel, Christoph H. Borchers, et al.

    Bile acids modulate the intestinal microbiota and serve as key signaling molecules in host physiology. Bile acid dysregulation has been implicated in nutritional and inflammatory diseases; however, data on the pool of bile acids present in stunted children or children suffering of environmental enteric dysfunction (EED) is limited, particularly in the upper intestinal compartment where disease phenotypes are most relevant. In this study, we performed a targeted metabolomics approach on 75 bile acids and their derivatives, including gastric and duodenal aspirates and fecal samples from almost 1000 children from two Sub-Saharan cities. We found that levels of secondary bile acids, especially lithocholic acid, are significantly lower in the feces of stunted and EED children, while ursocholic acid and its derivatives are significantly higher. Levels of primary and sulfated bile acids are also increased in the feces of children with EED. Microbiota sequencing revealed that high lithocholic acid levels are positively associated with butyrate-producing bacteria, while negatively associated with oral taxa like Streptococcus and Veillonella . In vitro tests on a panel of reference strains showed that oral bacteria bioaccumulate and are inhibited by a variety of bile acids, while lithocholic and chenodeoxycholic acids modulate the growth of several butyrate-producing bacteria. This effect was even stronger with tauro- or glycol-conjugated bile acids. Exposing stool-derived in vitro communities from children in Afribiota to these bile acids confirmed their positive impact on butyrate producers and negative effect on overgrowing oral taxa. Our findings suggest that secondary bile acids, reduced in stunting and EED, modulate the growth of butyrate-producing bacteria while suppressing harmful oral taxa, highlighting their potential as tools to modulate microbiota composition.

  • Open Access

    A host-directed virulence factor of Clostridium perfringens is modulated by gut commensal strains

    by Julia Schumacher, Paolo Stincone, Johanna Rapp, Timo-Niklas Lucas, Carlos Llaca-Bautista, Francesca Barletta, Mirita Franz-Wachtel, Boris Maček, Daniel H. Huson, Lisa Maier, et al.

    In a healthy host, the residential microbes help regulate the growth of pathobionts, which are common members of the human gut microbiome, preventing them from causing diseases, including infections, under certain conditions. In cases of dysbiosis, this protection may be compromised. Targeted microbiome modulation offers a promising approach to restore healthy conditions in a disrupted community and consequently prevent infections using the natural colonization resistance of the microbiome. Elucidating the interaction mechanisms between microbial species within a microbiome is crucial for understanding how a microbiome can be modulated precisely and effectively to benefit the host’s well-being. Here, we investigated the interactions between the pathobiont C. perfringens and human gut commensals on physiological and molecular levels. We found that commensal strains affect C. perfringens growth by competing for substrates such as amino acids or a carbon source other than glucose. We further observed that Bacteroidaceae strains altered the levels of C. perfringens proteins, among others, the host-directed θ-toxin. Our findings reinforce the notion that modulating the composition of the gut microbiome is an effective strategy to prevent infections.

  • Open Access

    A trait-based framework to identify microbial keystone taxa for microbiome engineering

    by Pamela Espíndola-Hernández, Samiran Banerjee, Abdulkabir O. Abdulmalik, Diana Andrade-Linares, Germana Baldi, Gabriele Berg, Francis Q. Brearley, Cecilia G. Flocco, Luisa Galgani, Lina Gegeckienė, et al.


  • Open Access

    A Functional Metabolomics Framework to Track Microbiome Drug Metabolism

    by Abzer K. Pakkir Shah, Anne Griesshammer, Paolo Stincone, Jarmo-Charles J Kalinski, Axel Walter, Mingxun Wang, Lisa Maier, Daniel Petras

    Understanding how gut microbes transform drugs, and how this influences microbiome composition and function, remains a key question to better understand the efficacy and side effects of pharmaceuticals. To accelerate the discovery of microbiome-derived drug metabolites, we developed a functional metabolomics workflow that combines the use of synthetic microbial communities (SynComs) with a time-series resolved molecular networking approach and advanced computational metabolite annotation. We demonstrate how this framework can be used to illuminate chemical transformation dynamics in a gut SynCom (Com20) with 50 clinical drugs. Our results highlight a multitude of drug metabolites, including multi-step metabolic cascades, some of which correlated to shifts in microbial taxa, suggesting functional links between microbiome composition and biochemical transformations. Our computational data analysis workflow is publicly available through the GNPS2 ecosystem at chemprop.gnps2.org, which can be used to prioritize biotransformations and other (bio)chemical reactions in various biological and abiotic systems.


  • Open Access

    Antagonistic drug interactions protect commensal Bacteroidaceae from macrolides via an RND-type efflux pump

    by Patrick Müller, Verena Schmidtchen, Jacobo de la Cuesta-Zuluaga, Lucía Pérez Jiménez, Cordula Gekeler, André Mateus, Lisa Maier

    Antibiotics are essential to modern medicine, but their broad-spectrum activity can unintentionally disrupt the gut microbiota. This collateral damage may be alleviated by antagonistic drug interactions, in which specific compounds used in combination therapies selectively protect beneficial gut microbes from antibiotic activity. Using efflux pump inhibitors, transcriptomic and proteomic analyses, and targeted gene deletions, we show that a variety of non-antibiotic pharmaceuticals-from diverse therapeutic classes and at sub-inhibitory concentrations-can protect multiple Bacteroidales species from macrolide antibiotics. In Bacteroidaceae, this protection is mediated by a resistance-nodulation-division (RND)-type efflux pump, which is induced by the non-antibiotic drug but not by macrolides alone. Notably, protection persists even after the non-antibiotic drug is removed, and prolonged exposure results in stable macrolide resistance that is dependent on the RND-type efflux pump. Our findings illustrate how non-antibiotic drugs can inadvertently activate otherwise silent detoxification systems in gut microbes, uncovering resistance mechanisms that arise without antibiotic selection or gene transfer. While this can be harnessed to protect the microbiome during antibiotic therapy, it also reveals hidden resistance phenotypes that may escape detection in standard antimicrobial resistance assays.


  • Open Access

    Consumption of low-digestible sugars increase susceptibility to Salmonella Typhimurium infection

    by Wolf-Dietrich Hardt, Bidong Nguyen, Sandra Wotzka, Lisa Maier, Céline Fetz, Yves Steiger, Elena Verdu, Nermin Akduman, Markus Arnoldini, Dorothée Berthold, et al.

    Low-digestible carbohydrates (LDCs), including dietary fibers and sugars that resist absorption, are generally considered beneficial for the gut microbiota. However, we show that ingestion of certain LDCs, particularly low digestible sugars (LDSs) such as arabinose, lactulose, and polyols commonly used as sugar substitutes (e.g., erythritol, maltitol, and sorbitol), can compromise colonization resistance against the common foodborne pathogen Salmonella enterica serovar Typhimurium. Acute overconsumption of these sugars results in elevated fecal pathogen loads, systemic dissemination, and colitis in infected mice. Focusing on arabinose, we found that rapid fermentation of this sugar acidifies the intestinal environment and shifts the microbiota composition. Metabolomic profiling revealed altered short-chain fatty acid levels and elevated availability of amino acids, which serve as carbon and nitrogen sources for pathogen growth. Arabinose consumption also impacts virulence by broadening tissue tropism, enhancing systemic infection, and selecting for fully virulent, invasive Salmonella through modulation of microbiota–pathogen interactions. These findings reveal how diet can impact the gut microbiota in ways that enhance pathogen colonization and virulence, posing potential risks for enteric infections.